China
· Delayed Price · Currency is CNY Haisco Pharmaceutical Group Statistics
Total Valuation
Haisco Pharmaceutical Group has a market cap or net worth of CNY 35.29 billion. The enterprise value is 36.06 billion.
| Market Cap | 35.29B |
| Enterprise Value | 36.06B |
Important Dates
The next estimated earnings date is Saturday, April 12, 2025.
| Earnings Date | Apr 12, 2025 |
| Ex-Dividend Date | Sep 18, 2024 |
Share Statistics
Haisco Pharmaceutical Group has 1.11 billion shares outstanding. The number of shares has increased by 1.13% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 1.11B |
| Shares Change (YoY) | +1.13% |
| Shares Change (QoQ) | +5.65% |
| Owned by Insiders (%) | 78.50% |
| Owned by Institutions (%) | 10.02% |
| Float | 228.44M |
Valuation Ratios
The trailing PE ratio is 73.62 and the forward PE ratio is 55.68.
| PE Ratio | 73.62 |
| Forward PE | 55.68 |
| PS Ratio | 9.42 |
| PB Ratio | 8.62 |
| P/TBV Ratio | 12.04 |
| P/FCF Ratio | 364.50 |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 57.95, with an EV/FCF ratio of 372.50.
| EV / Earnings | 75.73 |
| EV / Sales | 9.69 |
| EV / EBITDA | 57.95 |
| EV / EBIT | 94.90 |
| EV / FCF | 372.50 |
Financial Position
The company has a current ratio of 1.99, with a Debt / Equity ratio of 0.50.
| Current Ratio | 1.99 |
| Quick Ratio | 1.72 |
| Debt / Equity | 0.50 |
| Debt / EBITDA | 3.33 |
| Debt / FCF | 21.42 |
| Interest Coverage | 9.73 |
Financial Efficiency
Return on equity (ROE) is 13.22% and return on invested capital (ROIC) is 3.98%.
| Return on Equity (ROE) | 13.22% |
| Return on Assets (ROA) | 3.62% |
| Return on Capital (ROIC) | 3.98% |
| Revenue Per Employee | 683,255 |
| Profits Per Employee | 87,406 |
| Employee Count | 5,448 |
| Asset Turnover | 0.57 |
| Inventory Turnover | 3.50 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +41.91% in the last 52 weeks. The beta is 0.08, so Haisco Pharmaceutical Group's price volatility has been lower than the market average.
| Beta (5Y) | 0.08 |
| 52-Week Price Change | +41.91% |
| 50-Day Moving Average | 35.23 |
| 200-Day Moving Average | 31.59 |
| Relative Strength Index (RSI) | 32.08 |
| Average Volume (20 Days) | 3,651,855 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Haisco Pharmaceutical Group had revenue of CNY 3.72 billion and earned 476.19 million in profits. Earnings per share was 0.43.
| Revenue | 3.72B |
| Gross Profit | 2.69B |
| Operating Income | 380.00M |
| Pretax Income | 587.46M |
| Net Income | 476.19M |
| EBITDA | 615.33M |
| EBIT | 380.00M |
| Earnings Per Share (EPS) | 0.43 |
Balance Sheet
The company has 1.29 billion in cash and 2.07 billion in debt, giving a net cash position of -786.31 million or -0.71 per share.
| Cash & Cash Equivalents | 1.29B |
| Total Debt | 2.07B |
| Net Cash | -786.31M |
| Net Cash Per Share | -0.71 |
| Equity (Book Value) | 4.18B |
| Book Value Per Share | 3.69 |
| Working Capital | 1.43B |
Cash Flow
In the last 12 months, operating cash flow was 512.97 million and capital expenditures -416.16 million, giving a free cash flow of 96.81 million.
| Operating Cash Flow | 512.97M |
| Capital Expenditures | -416.16M |
| Free Cash Flow | 96.81M |
| FCF Per Share | 0.09 |
Margins
Gross margin is 72.17%, with operating and profit margins of 10.21% and 12.79%.
| Gross Margin | 72.17% |
| Operating Margin | 10.21% |
| Pretax Margin | 15.78% |
| Profit Margin | 12.79% |
| EBITDA Margin | 16.53% |
| EBIT Margin | 10.21% |
| FCF Margin | 2.60% |
Dividends & Yields
This stock pays an annual dividend of 0.29, which amounts to a dividend yield of 0.91%.
| Dividend Per Share | 0.29 |
| Dividend Yield | 0.91% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 1 |
| Payout Ratio | 88.72% |
| Buyback Yield | -1.13% |
| Shareholder Yield | -0.22% |
| Earnings Yield | 1.36% |
| FCF Yield | 0.27% |
Stock Splits
The last stock split was on September 12, 2013. It was a forward split with a ratio of 1.35.
| Last Split Date | Sep 12, 2013 |
| Split Type | Forward |
| Split Ratio | 1.35 |
Scores
Haisco Pharmaceutical Group has an Altman Z-Score of 7.97.
| Altman Z-Score | 7.97 |
| Piotroski F-Score | n/a |